No abstract

year period), and the incidence of new-onset diabetes similarly increased during that period (from 18%, 19.7%, 17.8%, 22.4%, to 23.3%). The incidence of acquired impaired fasting glucose or diabetes was significantly higher in obese or overweight patients than those without overweight (56.9% vs. 51.4%, p <0.001), but the incidence remained substantial in the latter group. Conclusions: The incidents of obesity and overweight increase significantly in both diabetic and non-diabetic new PD patients in Hong Kong over the past 25 years. The incident of new-onset glucose intolerance or diabetes also increased during this period in non-diabetic PD patients, especially amongst obese or overweight ones. The prognostic implication and impacts on the healthcare system deserve further studies.

BackgroundSerious burns produce plasma extravasation which develops an important loss of immunoglobulins (Ig). In patients with a burned surface area (BSA) >15% IgG plasmatic levels decrease until 40 hours’ post-burn.PurposeTo evaluate the use of non-specific Ig in burned paediatric patients based on the current protocol of the hospital.Material and methodsRetrospective observational study, which includes all paediatric patients with ≥15% BSA hospitalised between August 2012 and July 2017.Biodemographic data were registered as: (sex, age, weight), burn data (BSA) and Ig administration data (plasmatic levels, dose and number of administrations).The existing protocol about the use of Ig in burned paediatric patients (BSA ≥15%) was analysed. It recommends the determination of IgG 24 to 48 hours’ post-burn and the infusion of non-specific Ig (400 mg/kg) if patients have below-normal levels.ResultsThirty-one patients (12 females) with a median age of 2 years (8 m – 15 y) and a weight of 13 kg (7.5–67 kg) were enrolled in the study. The median BSA was 20% (15%–55%).Eighteen patients (58%) accomplished all the recommendations specified in the protocol.Determination of IgG levels was made in 26 patients (83.9%). Eighteen (69.2%) had below-normal levels and a median BSA of 23.5% (15–55). In the subgroup of patients with BSA ≥20% (20–55) the determination was done in the 94% (15/16) and 14 (93%) who had below-normal levels.Non-specific Ig was administered in 61% (19) of the patients at a dose of 400 mg/kg. No IgG determination was repeated after the first infusion in six patients (31.6%). Seven patients with a median BSA of 46% (16–55) needed more than one Ig infusion.ConclusionAll patients received the dose of Ig indicated in the protocol (400 mg/kg).In patients with BSA>20%, determination of plasmatic levels is essential because it was detected that more than 90% of the patients had below–normal levels of IgG.No IgG determination after the first infusion was repeated in more than 30% of the patients, therefore a proposal to improve the protocol is the need to repeat IgG determination in all the patients who have received an infusion to corroborate the achievement of normal IgG levels.References and/or AcknowledgementsThanks to all authorsNo conflict of interest

No abstract